To Study And Compare Bioavailability And Safety Of Four Different Formulations Of The Study Drug

Completed

Conditions studied: Healthy Subjects

In brief

SB-742510 is a semi-synthetic pleuromutilin antibiotic that is being developed for treatment of respiratory infections. The purpose of this study is to estimate the bioavailability of four different formulations and to evaluate the safety of each of the four formulations

Key facts

Study ID

NCT00436228

Run by

GlaxoSmithKline

People needed

32

Starts

2006-11-01

Expected to finish

2007-02-01

Last updated by the study team

2008-10-13

Who can join

Age: 18 and older, up to 60. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Healthy as determined by a responsible physician, based on medical evaluations performed at screening.
• Healthy adults between 18 and 60 years of age, inclusive.
• Body weight proportional to height.
• Capable of giving written informed consent.
• Female subjects must be of non-childbearing potential.
• QTc less than 450 msec at screening

You may not qualify if…

• Any clinically relevant abnormality identified on the screening history and physical or on the 12-lead surface electrocardiogram at screening or pre-dose.
• The subject has a positive pre-study alcohol/urine drug screen.
• History of regular use of tobacco, or nicotine-containing products.
• A positive pre-study HIV antibody, Hepatitis B surface antigen (HBsAg) or Hepatitis C antibody result within 3 months of screening.
• Use of certain prescription or non-prescription drugs, including vitamins, herbal and dietary supplements.
• An unwillingness to comply with lifestyle and/or dietary restrictions.

Where it is running

• GSK Investigational Site — Tacoma, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.